Parsons Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.87M Buy
80,285
+6,828
+9% +$398K 0.22% 97
2025
Q4
$3.96M Buy
73,457
+443
+0.6% +$21.3K 0.22% 105
2025
Q3
$3.29M Sell
73,014
-5,091
-7% -$238K 0.19% 119
2025
Q2
$3.62M Buy
78,105
+224
+0.3% +$11K 0.22% 100
2025
Q1
$4.75M Sell
77,881
-1,622
-2% -$94.5K 0.26% 78
2024
Q4
$4.5M Sell
79,503
-4,665
-6% -$261K 0.24% 82
2024
Q3
$4.35M Sell
84,168
-9,917
-11% -$465K 0.28% 77
2024
Q2
$3.91M Sell
94,085
-5,566
-6% -$249K 0.27% 85
2024
Q1
$5.4M Sell
99,651
-25,677
-20% -$1.31M 0.37% 63
2023
Q4
$6.43M Sell
125,328
-354
-0.3% -$18.6K 0.46% 44
2023
Q3
$7.29M Sell
125,682
-3,611
-3% -$221K 0.58% 36
2023
Q2
$8.27M Buy
129,293
+1,415
+1% +$94.9K 0.63% 32
2023
Q1
$8.86M Buy
127,878
+4,179
+3% +$295K 0.71% 25
2022
Q4
$8.9M Buy
123,699
+3,632
+3% +$274K 0.74% 25
2022
Q3
$8.54M Buy
120,067
+5,618
+5% +$408K 0.77% 26
2022
Q2
$8.81M Buy
114,449
+1,496
+1% +$114K 0.79% 26
2022
Q1
$8.25M Buy
112,953
+851
+0.8% +$57.1K 0.62% 33
2021
Q4
$6.99M Sell
112,102
-5,782
-5% -$339K 0.5% 42
2021
Q3
$6.97M Buy
117,884
+7,321
+7% +$482K 0.55% 39
2021
Q2
$7.39M Sell
110,563
-1,094
-1% -$71.3K 0.57% 37
2021
Q1
$7.05M Sell
111,657
-465
-0.4% -$28.9K 0.58% 37
2020
Q4
$6.96M Buy
112,122
+3,813
+4% +$234K 0.6% 36
2020
Q3
$6.53M Sell
108,309
-23
-0% -$1.38K 0.64% 32
2020
Q2
$6.37M Buy
108,332
+358
+0.3% +$21.4K 0.68% 33
2020
Q1
$6.02M Sell
107,974
-4,991
-4% -$305K 0.78% 28
2019
Q4
$7.25M Buy
112,965
+59,360
+111% +$3.4M 0.73% 29
2019
Q3
$2.72M Sell
53,605
-701
-1% -$32.9K 0.29% 82
2019
Q2
$2.46M Sell
54,306
-845
-2% -$39.4K 0.27% 90
2019
Q1
$2.63M Sell
55,151
-697
-1% -$34.7K 0.29% 85
2018
Q4
$2.9M Sell
55,848
-1,786
-3% -$96K 0.36% 68
2018
Q3
$3.58M Sell
57,634
-820
-1% -$48.7K 0.38% 67
2018
Q2
$3.23M Sell
58,454
-1,185
-2% -$64K 0.37% 70
2018
Q1
$3.77M Sell
59,639
-542
-0.9% -$34.9K 0.44% 57
2017
Q4
$3.69M Sell
60,181
-100
-0.2% -$6.25K 0.41% 64
2017
Q3
$3.84M Buy
60,281
+824
+1% +$48.1K 0.45% 55
2017
Q2
$3.31M Sell
59,457
-825
-1% -$44.9K 0.4% 61
2017
Q1
$3.28M Sell
60,282
-1,000
-2% -$54.8K 0.41% 57
2016
Q4
$3.58M Sell
61,282
-965
-2% -$52.8K 0.48% 48
2016
Q3
$3.36M Sell
62,247
-2,055
-3% -$132K 0.45% 52
2016
Q2
$4.73M Sell
64,302
-2,945
-4% -$208K 0.64% 40
2016
Q1
$4.3M Sell
67,247
-350
-0.5% -$22.1K 0.59% 43
2015
Q4
$4.65M Sell
67,597
-961
-1% -$63.5K 0.65% 41
2015
Q3
$4.06M Sell
68,558
-75
-0.1% -$4.76K 0.59% 44
2015
Q2
$4.57M Sell
68,633
-202
-0.3% -$13.3K 0.61% 42
2015
Q1
$4.44M Buy
68,835
+741
+1% +$46.4K 0.62% 35
2014
Q4
$4.02M Sell
68,094
-1,229
-2% -$69.3K 0.53% 47
2014
Q3
$3.55M Sell
69,323
-1,565
-2% -$78.2K 0.49% 53
2014
Q2
$3.44M Sell
70,888
-528
-0.7% -$26K 0.47% 54
2014
Q1
$3.71M Sell
71,416
-1,493
-2% -$79.4K 0.53% 49
2013
Q4
$3.88M Sell
72,909
-616
-0.8% -$31.4K 0.58% 45
2013
Q3
$3.4M Buy
73,525
+636
+0.9% +$27.9K 0.56% 49
2013
Q2
$3.26M Buy
+72,889
New +$3.16M 0.56% 49

Other funds holding BMY

Parsons Capital Management's BMY Position: Q1 2026 in Review

Parsons Capital Management increased its Bristol-Myers Squibb (BMY) stake by 9.3% in Q1 2026, buying an estimated $398K and bringing the position to 80,285 shares worth $4.87M. The position accounts for 0.22% of the portfolio, ranked #97.

Parsons Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.9M in Q4 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Parsons Capital Management held 80,285 shares of Bristol-Myers Squibb worth $4.87M as of Q1 2026.
  • Parsons Capital Management bought 6,828 Bristol-Myers Squibb shares in Q1 2026, an estimated $398K.
  • Bristol-Myers Squibb made up 0.22% of Parsons Capital Management's portfolio in Q1 2026, its #97 holding.
  • Parsons Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Parsons Capital Management's Bristol-Myers Squibb position peaked at $8.9M in Q4 2022.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Parsons Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.